An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44 percent compared with Merck’s immunotherapy Keytruda alone, U.S. researchers reported at a medical meeting on Sunday.
The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which revs up the immune response, could prolong the time patients have without recurrence or death, said Dr Jeffrey Weber, NYU Langone Perlmutter Cancer Center, who presented the findings.
For more details, check out the link given below:
Moderna, Merck Cancer Vaccine Plus Keytruda Delays Skin Cancer Return
GIPHY App Key not set. Please check settings